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adverse effects proﬁle of the medication. The most support was registered for the 
optimal scenario (halt disease progression, no adverse effects).
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MIGRAINE: PRESCRIBING PATTERNS IN A SOUTH AFRICAN PRIMARY 
CARE PATIENT POPULATION
Truter I
Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa
OBJECTIVES: Migraine affects 8% to 14% of the population in Western countries. 
It affects primarily the young adult population and is responsible for many lost 
working days each year since it affects primarily the economically active sector of the 
community. The primary aim of the study was to determine the prescribing patterns 
and cost of drugs for migraine in a primary care patient population. METHODS: A 
retrospective drug utilisation consumption study was conducted. Data were obtained 
from a South African private health care group. The database consisted of all central 
nervous system medicine for 2008. RESULTS: A total of 22102 patients (71.05% 
females) received 43144 items for migraine a cost of R3622552 (average cost of 
R83.96 per item). The average age of patients was 44.90 (SD  13.83) years, with 
70.76% of patients between 30 and 59 years of age. The chi-square test was used to 
detect prescribing differences between female and male patients in different age groups 
(chi2  212.31; d.f.  6; p  0.0001). Differences were observed in prescribing to female 
and male patients. Patients were prescribed an average of 1.95 items for migraine over 
the year. The Lorenz curve was used to illustrate skewness in prescribing. Clonidine 
was the most frequently prescribed active ingredient (46.15%), followed by cyclizine 
(29.62%). The agents for the prophylaxis of migraine (clonidine, ﬂunarizine and 
pizotifen) accounted for 50.48% of prescribing frequency and 29.04% of cost. The 
selective 5HT1-receptor agonists (triptans) accounted for 18.94% of prescribing fre-
quency and 53.54% of cost. Rizatriptan was the most frequently prescribed triptan. 
CONCLUSIONS: The ﬁndings were generally in agreement with two other South 
African studies, although differences were observed. A lower prescribing rate for 
triptans has been observed. Qualitative studies on migraine are needed in South Africa 
to determine its impact on the quality of life of patients.
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OBJECTIVES: Chronic low back pain (CLBP) is a major cause of disability, affecting 
mainly working-age adults and imposing a large economic burden on society. Since 
no consensus exists regarding standard of care for this condition, the objective of this 
study was to systematically review the efﬁcacy and safety of pharmacotherapies used 
for CLBP. METHODS: A systematic literature review was conducted through July/
August 2008, searching MEDLINE, EMBASE, and bibliographic details of relevant 
studies. Prospective trials and observational studies were included if they assessed 
pharmacotherapies in adults with CLBP and were written in English. Efﬁcacy end-
points included: pain relief, pain interference with activities, individual’s functioning 
and response to treatment. Adverse event (AE) rates and withdrawal rates due to AEs 
were also assessed. Extensive study heterogeneity prohibited quantitative synthesis. 
RESULTS: From 773 citations screened, 65 studies (published between 1982 and 
2008) were selected, of which 54 were randomized controlled trials. The efﬁcacy 
measures most consistently reported across studies included the visual analogue scale 
(VAS) and the Roland Morris Disability Questionnaire (RMDQ). Non-steroidal 
anti-inﬂammatory drugs (NSAIDs), weak and strong opioids, several antidepressants 
(clomipramine, mianserin, and duloxetine titrated based on patient response and toler-
ability), the anticonvulsant topiramate, and certain transdermal medications (trans-
dermal fentanyl and lidocaine patches) signiﬁcantly reduced pain intensity. The 
effectiveness of injections (i.e., glucose and lidocaine) and other antidepressants (par-
oxetine, trazodone or bupropion) was uncertain. Regarding patient functioning, sig-
niﬁcant improvements were observed for NSAIDs, opioids and duloxetine, but not for 
local injections. The magnitude of effect of these endpoints ranged from small to 
moderate, depending on the pharmacotherapy assessed. CONCLUSIONS: NSAIDs, 
opioids, some antidepressants, an anticonvulsant and certain transdermal medications 
seemed to signiﬁcantly reduce pain intensity in CLBP, while inconclusive results were 
obtained for other antidepressants and local injections. Overall, the study ﬁndings 
were consistent with current guideline recommendations from Europe and US.
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OBJECTIVES: Propoxyphene is among the most commonly prescribed opioid anal-
gesic in the elderly. However, many guidelines, including the American Geriatric 
Society and Beer’s List of Potentially Inappropriate Medications, recommend restrict-
ing its use in that age group. These guidelines are based on expert opinions with limited 
empirical evidence. The objective of this study was to evaluate whether there were 
differences in adverse event reporting for propoxyphene by age group using a large 
post-marketing safety surveillance data. METHODS: Analysis was conducted using 
the 2005–2008 Adverse Event Reporting System (AERS) data in the US, which was 
developed to support the FDA’s post-marketing safety surveillance program for all 
approved products. Adverse events reported with propoxyphene as primary, second-
ary or interacting drug were categorized into central nervous system (CNS) and gas-
trointestinal (GI) adverse events (AEs). Logistic regressions were used to assess the 
risk of CNS and GI adverse events (AEs) among the elderly (age   65) and younger 
patients (age  65) controlling for gender and those reporting the AEs. Proportional 
reporting ratios (PRR) for the propoxyphene-AE combination were also computed for 
the elderly and younger patients. RESULTS: In the period 2005–2008, a total of 2497 
propoxyphene-AE combinations were reported, 261 were CNS-related and 127 were 
GI-related. In multivariate analysis, controlling for gender and those reporting the 
AEs, no signiﬁcant differences were observed in the risk of CNS-related AEs (Odds 
ratio: 0.827; 95% CI: 0.619–1.105; p  0.199) or GI-related AEs (Odds ratio: 1.216; 
95% CI: 0.832–1.778; p  0.313) among elderly versus young patients. Among the 
elderly, the PRR for propoxyphene-CNS AEs was 0.795 and the PRR for propoxy-
phene-GI AEs was 0.596. These were similar to the PRRs among younger patients, 
which were 0.700 and 0.439, respectively. CONCLUSIONS: Using a voluntary post-
marketing surveillance database, the study found no differences in the extent of CNS 
AEs and GI AEs reported with propoxyphene among elderly patients versus younger 
patients.
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OBJECTIVES: To determine payments made by commercial health care providers for 
adults diagnosed with obesity, and those who are comorbid with any combination of 
the following chronic conditions: diabetes mellitus (DM), hypertension, depression, 
and/or congestive heart failure (CHF). METHODS: We utilized a 10% random sam-
pling from a commercial claims and encounters database (n  12,416,190). The study 
population (n  50,717) was limited to those who: 1) were adults age 18–64; 2) ﬁled 
a claim between 2006–2007; 3) had at least one inpatient visit, one outpatient visit, 
or one emergency department visit; and; 4) had been given a primary or secondary 
diagnosis of obesity. Persons were identiﬁed and categorized if they had one or more 
comorbid diagnoses (DM, hypertension, depression, and/or CHF) in addition to 
obesity. After adjusting for age and gender, we calculated the mean total net expen-
ditures (in $US 2007) for each combination of comorbid conditions. All calculations 
were performed in Stata. RESULTS: Among those diagnosed with obesity, the mean 
net expenditures for services were $1799 per patient. Persons diagnosed with obesity 
and other comorbidities observed an increase in total net expenditures. Obesity and 
hypertension observed the highest increase among single comorbidities at $4298. For 
persons with obesity and two other comorbidities, DM and depression was the highest 
at $14,364. The most expensive condition in the study sample was obesity, DM, 
hypertension and depression at $14,843. All results were statistically signiﬁcant at the 
95% conﬁdence level. CONCLUSIONS: Compared to the average medical claim, 
persons diagnosed with obesity along with other common chronic conditions experi-
ence signiﬁcant increases in health care costs. These costs are often driven higher by 
the time spent as inpatients. In many cases, obesity may be the cause of other chronic 
conditions that result in these high costs. Thus, by controlling and reducing the preva-
lence of obesity, we may see signiﬁcant decreases in health care expenditures.
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OBJECTIVES: Treatment of patients with acute myeloid leukemia (AML) is based 
upon stratiﬁcation into risk (prognosis) groups. New diagnostic methods are in devel-
opment to improve this stratiﬁcation. Economic evaluations of these methods require 
knowledge of what happens when the current stratiﬁcation methods are used. We 
examined whether the literature can provide valid estimates for the outcomes 
of complete remission rates for patients with primary AML aged 16–60 years. 
METHODS: A systematic literature review was performed using Pubmed and Embase. 
Inclusion criteria were: q100 AML patients and detailed outcomes per risk group 
(favorable, intermediate, unfavorable). Excluded were: Phase I/II studies, studies not 
containing any patients aged 16–60 years or with primary AML. We compared various 
study characteristics such as patient population, treatment given, risk group deﬁnitions 
and complete remission (CR) rates as outcome. A chi-square test for homogeneity of 
CR rates was performed. RESULTS: Twelve studies fulﬁlled the eligibility criteria. 
Great variation was found between study populations. While treatment varied between 
the studies, all patients received cytarabine and an anthracycline. Deﬁnitions of risk 
groups varied greatly except for the favorable risk group. There was no homogeneity 
in overall CR rate (range: 52–85% p  0.001). After excluding studies with many 
patients other than the target population, heterogeneity between the remaining studies 
decreased (N  7, p  0.083). CR rates were homogeneous in the favorable group (p 
 0.223), but heterogeneous in the intermediate and unfavorable groups (p  0.044 
and p  0.096 respectively). CONCLUSIONS: Differences in patient population and 
